Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study

News
Article

An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.

Currently being studied for use with dynamic contrast-enhanced magnetic resonance imaging (DCE MRI), an emerging artificial intelligence (AI) algorithm may offer significant benefit in breast cancer detection.

In a multicenter study presented at the Society for Breast Imaging (SBI) conference, researchers assessed the AI algorithm in 8,409 DCE MRI exams. The cohort included 1,305 cases of breast cancer, 319 breasts with benign lesions and 14,988 normal breasts, according to the study.

The study authors found that the AI algorithm provided a pooled 93.9 percent area under the receiver operating characteristic curve (AUC), For BI-RADS 3 cases, the researchers noted the AL algorithm provided an 87 percent AUC, 92.3 percent sensitivity and 81.6 percent specificity.1

Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study

In a multicenter study involving over 8,400 patients who had dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) exams, researchers found that an emerging artificial intelligence (AI) algorithm demonstrated a 99.7 percent negative predictive value (NPV) for cases involving normal breasts. (Images courtesy of the Society for Breast Imaging.)

The AI algorithm also had a negative predictive value (NPV) of 99.7 percent for breasts classified as normal breasts, according to the study authors.1

“A first evaluation of an AI system for abbreviated DCE-MRI shows potential for decision support in detecting breast cancer and particularly for accurate identification of very likely normal exams with a consistent performance among different levels of background parenchymal enhancement (BPE),” noted lead study author Koen A.J. Eppenhof, Ph.D., clinical and AI innovation lead with ScreenPoint Medical, and colleagues.

For the 1709 cases in the cohort with documented BPE, the study authors noted an 85.4 percent AUC with cases involving moderate BPE and an 86.6 percent AUC for MRI scans showing marked BPE.1

(Editor’s note: For related content, see “Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?,” “Abbreviated Breast MRI and Dense Breasts: What Emerging Research Reveals” and “Can AI Automate BPE Assessment of Dense Breasts on MRI?”)

The researchers also found that the AI algorithm performed well across four different MRI vendors with an average AUC of 94.5 percent.1

“AI tools to support radiologists reading breast MRI could improve workflow by improving specificity and reducing reading time,” added Eppenhof and colleagues.

Reference

1. Eppenhof KAJ, Rodriguez-Ruiz A, Boxtel JV, et al. Multi-site validation of a novel AI system for cancer detection in breast MRI. Presented at the Society for Breast Imaging (SBI) conference, April 24-27, 2025, Colorado Springs, Colo. Available at: https://www.sbi-online.org/events/2025-sbi-breast-imaging-symposium . Accessed April 25, 2025.

Recent Videos
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.